Context Clinicians have observed various patterns of functional decline at the
end of life, but few empirical data have tested these patterns in large populations.
Objective To determine if functional decline differs among 4 types of illness
trajectories: sudden death, cancer death, death from organ failure, and frailty.
Design, Setting, and Participants Cohort analysis of data from 4 US regions in the prospective, longitudinal
Established Populations for Epidemiologic Studies of the Elderly (EPESE) study.
Of the 14 456 participants aged 65 years or older who provided interviews
at baseline (1981-1987), 4871 died during the first 6 years of follow-up;
4190 (86%) of these provided interviews within 1 year before dying. These
decedents were evenly distributed in 12 cohorts based on the number of months
between the final interview and death.
Main Outcome Measures Self- or proxy-reported physical function (performance of 7 activities
of daily living [ADLs]) within 1 year prior to death; predicted ADL dependency
prior to death.
Results Mean function declined across the 12 cohorts, simulating individual
decline in the final year of life. Sudden death decedents were highly functional
even in the last month before death (mean [95% confidence interval {CI}] numbers
of ADL dependencies: 0.69 [0.19-1.19] at 12 months before death vs 1.22 [0.59-1.85]
at the final month of life, P = .20); cancer decedents
were highly functional early in their final year but markedly more disabled
3 months prior to death (0.77 [0.30-1.24] vs 4.09 [3.37-4.81], P<.001); organ failure decedents experienced a fluctuating pattern
of decline, with substantially poorer function during the last 3 months before
death (2.10 [1.49-2.70] vs 3.66 [2.94-4.38], P<.001);
and frail decedents were relatively more disabled in the final year and especially
dependent during the last month (2.92 [2.24-3.60] vs 5.84 [5.33-6.35], P<.001). After controlling for age, sex, race, education,
marital status, interval between final interview and death, and other demographic
differences, frail decedents were more than 8 times more likely than sudden
death decedents to be ADL dependent (OR, 8.32 [95% CI, 6.46-10.73); cancer
decedents, one and a half times more likely (OR, 1.57 [95% CI, 1.25-1.96]);
and organ failure decedents, 3 times more likely (OR, 3.00 [95% CI, 2.39-3.77]).
Conclusions Trajectories of functional decline at the end of life are quite variable.
Differentiating among expected trajectories and related needs would help shape
tailored strategies and better programs of care prior to death.
Clinical observation supports the existence of differences in functional
decline before dying. Although these differences may have important implications
for the organization and delivery of care at the end of life, little empirical
work examines such patterns across large populations.
In 1968, Glaser and Strauss1 described
3 different trajectories of dying: abrupt, surprise deaths; expected deaths
(both short-term and lingering); and entry-reentry deaths, where individuals
slowly decline but return home between stays in the hospital. More recently,
these ideas have been expressed as a set of functional trajectories2-4 in which short-term
expected deaths (terminal illness) are portrayed separately from lingering
expected deaths (frailty). The 4 theoretical trajectory groups in Figure 1 were operationalized in an analysis
of Medicare claims data and had distinctly different patterns of demographic
characteristics, care delivery, and Medicare expenditures.2 However,
to our knowledge, no study has evaluated whether patients in these 4 groups
actually differ in the slope of decline in physical function before death.
Earlier research documented that those who are dying experience a steeper
decline in functional status than do same-age survivors.5-7 Functional
decline before death differs by age6 and, among
the chronically ill, medical conditions influence the pattern of functional
disability.8-15 A
recent study found a sharper terminal decline in function in the last months
of life for cancer decedents compared with those dying from other chronic
illnesses.16 The current study extends this
work with more in-depth analysis of the role of different diseases and conditions
related to dying in older age.
We analyzed data from 4 areas from the Established Populations for Epidemiologic
Studies of the Elderly (EPESE) study: East Boston, Mass; Washington and Iowa
counties, Iowa; New Haven, Conn; and 5 contiguous rural counties of north
central North Carolina. The EPESE followed community-based cohorts of persons
aged 65 years or older with baseline in-person interviews conducted between
1981 and 1987 followed by 6 to 10 annual in-person or telephone follow-up
interviews. Others have described the design and data collection methods in
detail.17,18 Of the 14 456
EPESE participants who were interviewed at baseline, 4871 died during the
first 6 years of the follow-up period and a date of death is available for
4865. The group of 4190 decedents (86%) who happened to be interviewed within
1 year before death constitutes the sample population for these analyses.
Those 4190 did not differ from the remaining decedents in age at death or
any other demographic characteristics.
Each interview included self-reported or proxy-reported physical function.
At baseline, 99% of decedents participated directly in the interview process.
Proxies provided data for the last follow-up interview of 26% of the decedents,
who were too cognitively or physically impaired to participate directly at
that point. Interviewers asked if participants needed help or were unable
to perform each of the following 7 activities of daily living (ADLs): walking
across a small room, bathing, grooming, dressing, eating, transferring from
bed to chair, and using the toilet. In addition, questions ascertained their
ability to walk a half mile; stoop, kneel, or crouch; climb a flight of stairs;
and do heavy housework, such as washing floors. Each year, participants also
reported on a variety of other health issues, such as the new diagnosis of
a chronic illness (cancer, heart disease, or diabetes), or the occurrence
of a hip fracture, stroke, hospitalization, or nursing home stay during the
preceding year. We have death certificate data for 4865 of the 4871 decedents.
The 4190 EPESE decedents who provided interview data during their final
year of life were evenly distributed in 12 cohorts based on the number of
months between the participant's final interview and death, with 6.6% to 8.2%
interviewed in any particular month. Of particular interest, 315 were interviewed
12 months before death and 316 in the final month of life. We derived functional
patterns from the mean number of ADL dependencies for each monthly cohort.
We also grouped decedents into categories corresponding to the 4 theoretical
trajectories based on information from the death certificate and from interviews.
Decedents with a diagnosis of cancer (International Classification
of Diseases, Ninth Revision [ICD-9] codes 140.0-239.9) noted as the
immediate or underlying cause of death on their death certificate constituted
the cancer group. Decedents with congestive heart failure (ICD-9 codes 428.0-428.9) or chronic lung disease (ICD-9 codes 490.0-496.9) in any diagnosis field on the death certificate
made up the organ failure group. Those decedents who had reported a nursing
home stay during any follow-up interview comprised the frailty group. The
sudden death group consisted of those who died with no diagnosis of cancer
or organ failure on the death certificate, with no nursing home stay, and
who had reported no history of the following at any point during the study:
cancer, heart disease, diabetes, hip fracture, or stroke. Remaining (unclassified)
decedents formed the "other" group.
Because comorbidity is common among elderly patients, we expected overlap
among the cancer, organ failure, and frailty decedents (the only groups with
the potential for overlap). Therefore, we forced unique decedent group membership
by sequentially identifying each category and removing those decedents from
the pool before identifying the next category. We chose the hierarchy of cancer>organ
failure>frailty, based on the expectation that cancer would be the dominant
illness when it is listed as the immediate or underlying cause of death. We
found that all demographic characteristics and patterns of functional decline
attributed to a decedent group were consistent regardless of whether the groups
were independently identified with overlap allowed or sequentially defined,
and, when sequentially defined, regardless of which order was used to define
and remove the decedent groups. The characteristics of these trajectory groups
were notably consistent regardless of the specific way in which they were
defined.
We compared descriptive characteristics among the groups using analysis
of variance with a Bonferroni correction for multiple comparisons. In addition
to describing the demographic characteristics of the categorized decedents
and plotting the decline in physical function as the cohort interval approached
the date of death, we developed a logistic regression model to examine the
importance of decedent group membership in predicting the likelihood of being
disabled before dying, adjusting for the effects of age, sex, race, education,
marital status, and the amount of time between the final interview and death.
We defined disability as requiring assistance with or being unable to perform
any ADL. The group expected to be least disabled (men who died suddenly at
ages 65-74 years) was chosen as the reference group. As with the descriptive
analyses, the regression model was found to be consistent across each different
decedent classification approach. Results reported here are for decedent classification
in the following order: sudden death, cancer, organ failure, frailty, and
other.
Compared with participants in EPESE who survived the first 6 years of
the follow-up period, those who died were significantly older at baseline
(77.0 vs 72.6 years, P<.001) and more likely to
be men (47% vs 33%, P<.001) and single (56% vs
49%, P<.001). At baseline, decedents also reported
a higher number of the following previous medical conditions: history of cancer,
heart disease, diabetes, hip fracture, or stroke (0.76 vs 0.44, P<.001). Years of education and percentage of nonwhite race did
not differ between decedents and survivors.
Among the 4190 decedents who happened to have interviews during the
final year of life, the decedent group sizes were as follows when sequentially
identified: sudden death (n = 649 [15%]), cancer (n = 897 [21%]), organ failure
(n = 817 [20%]), frail (n = 837 [20%]), and other (n = 990 [24%]). When allowed,
overlap existed primarily among the organ failure and frailty groups (n =
320 [8%]) and the cancer and frailty groups (n = 202 [5%]).
Among the decedent groups, cancer decedents were the youngest group
(Table 1). Death from cancer peaked
before age 80 years, and 79% were younger than 85 years when they died. Organ
failure decedents were also significantly older, whereas members of the sudden
death and unclassified groups were younger than the mean age. Those classified
as frail were the oldest. Of these, 77% were aged 80 years or older, and the
distribution among age groups increased steadily with each incremental increase
in age. Frail decedents were most likely to be women and least likely to be
currently married. The unclassified or "other" decedents had the most coexisting
medical conditions.
For all decedents, mean function declined across the 12-month–based
subgroups in a pattern that could be expected to represent mean individual
decline in the final year of life. With decedents grouped into 3 age categories
(65-74 years, 75-84 years, and ≥85 years), the overall level of dependency
was greater with increasing age, but the trajectory of ADL dependence followed
a similar slope of decline for each age group. Similarly, sex differences
existed in the amount of disability but not in the slope of decline in the
last year of life. As has been well documented by others,19,20 women
in this study were consistently more disabled than their male counterparts.
No differences in functional disability prior to death associated with race
or level of education were significant.
Figure 2 shows patterns of
observed ADL disability for each of the 4 trajectory-based groups. Those in
the sudden death group were substantially more independent and these cohorts
did not decline in function as death approached. The mean (95% confidence
interval [CI]) number of ADL disabilities for those interviewed in the final
month of life (1.22 [0.59-1.85]) was not significantly different from that
for those interviewed 12 months before death (0.69 [0.19-1.19]) (P = .20). Cancer decedents also experienced better functional status
early in the final year, but those interviewed during the 3 months before
death were markedly more disabled. Individual variation in functional ability
during any 1-year period fits with the clinical pattern of disease exacerbations
associated with congestive heart failure and chronic obstructive pulmonary
disease. However, this study examined only mean group disability and this
also declined erratically for the organ failure decedents. Decedents in the
frailty group were relatively more disabled throughout the last year of life.
Like the cancer group, both the organ failure and frailty groups demonstrated
a substantial decline in function during the last 3 months of life. For all
3 of these groups, those interviewed in the final month of life were significantly
more disabled than those interviewed 12 months before death (cancer: 4.09
[3.37-4.81] vs 0.77 [0.30-1.24]; organ failure: 3.66 [2.94-4.38] vs 2.10 [1.49-2.70];
frailty: 5.84 [5.33-6.35] vs 2.92 [2.24-3.60]; P<.001
for all).
The decedents who met none of the classification criteria (ie, the "other"
group) showed a pattern of modest and gradual decline in independence during
the final year of life. Those interviewed 12 months before death reported
dependence in 1.23 (95% CI, 0.77-1.69) of 7 activities; those interviewed
in the final month of life reported a mean of 2.27 (95% CI, 1.58-2.96) dependencies.
Of these unclassified decedents, 395 (40%) had ischemic heart disease noted
as the underlying cause of death, whereas this rate of ischemic heart disease
was 27% across the full decedent pool. The pattern of modest, gradual functional
decline in the unclassified group closely matched the pattern of decline we
found when we evaluated all ischemic heart disease decedents (n = 1140) as
a single decedent group. Among decedents who had had ischemic heart disease
noted in any field on the death certificate, those interviewed 12 months before
death reported dependence in 0.74 (95% CI, 0.35-1.13) of 7 activities; those
interviewed in the last month of life reported a mean of 2.38 (95% CI, 1.28-2.98)
dependencies.
In the multiple logistic regression model of ADL dependency, assignment
to a trajectory category continued to be a very strong predictor of disability
even after controlling for age, sex, race, education, marital status, and
the interval between the final interview and death (Table 2). Not surprisingly, decedents aged 85 years or older were
4 times more likely to require assistance as those aged 65 through 74 years.
Women were more than one and a half times more likely to be dependent than
were men. Yet, after controlling for these and other demographic differences,
those assigned to the frailty group were more than 8 times more likely to
be ADL dependent than those who died suddenly.
The empirical trajectories of functional decline for the 4 categories
of decedents differed markedly and were very similar to the previously published
theoretical model. The scheme is clinically intuitive and the possible existence
of these different pathways to death has important implications for health
care delivery. Only short-term expected deaths, such as may occur with cancer
decedents, are likely to have a predictable terminal period that meets the
public expectation of dying and the health care requirements for hospice care.
Those who experience entry-reentry deaths or lingering deaths may also need
the supportive services offered by hospice care, but hospice reimbursement
requires the certainty of a limited lifespan. Additional data about functional
trajectories of dying will better inform both health care practice and delivery
of service at the end of life.
Prospective, longitudinal data collected from a population-based sample
at high risk of death provides an important opportunity to learn from retrospectively
examining lives before both predictable and unpredictable death. The ideal
data set would require frequent measures (at least quarterly) on all high-risk
individuals for many years, thereby generating multiple data points in the
year before each death. Unfortunately, such research is prohibitively expensive
to conduct with large, population-based samples. On the other hand, with a
large number of annual follow-up interviews and a sufficient sample size,
the EPESE study allowed an alternative approach: analyses from multiple subgroups
of the sample, each of which had data collected at a similar time point in
the final year of life. Though limited to group analyses, this viewpoint permits
a useful examination of functional decline from prospectively collected data.
This study and our previous analysis of Medicare claims data2 demonstrate the importance of recognizing differences
in the trajectories or clinical course that people can experience in the last
phase of life. However, these studies also highlight the conceptual and operational
challenges associated with attempts to create distinct categories from a complex
event such as death, especially among elderly individuals. Defining frailty
is a particular challenge. In this study, after first removing cancer and
organ-failure decedents, we classified 20% of the decedents as frail using
evidence of a nursing home stay as the defining criterion. Using a similar
procedure in our previous analyses, we classified 47% as frail with the criterion
of a Medicare claim listing 1 condition from a previously published list of
conditions commonly associated with slowly declining health.21 As
a proxy for frailty, nursing home utilization has some face validity, but
it undoubtedly underestimates the frail population and tends to present a
circular argument when ADLs serve as the outcome measure. Unfortunately, diagnoses
on death certificates do not currently offer a reasonable alternative approach
for the identification of frail elderly decedents.
These findings encourage further exploration of the possibility of a
fifth conceptually distinct trajectory of dying: one in which individuals
experience a steady decline in function but at a moderately high level of
performance. This trajectory arose in the unclassified group and also among
all decedents with ischemic heart disease as the underlying cause of death.
A better understanding of the importance of this type of decline and the role
of heart disease in functional decline at the end of life will require more
comprehensive clinical data than are available in the EPESE study.
Even with these limitations, this empirical validation of the existence
of different trajectories of dying is an important first step in getting beyond
the "one-size-fits-all" model for end-of-life care and research. The public
image of dying and most scientific evidence for care at the end of life come
from studies of those diagnosed with a terminal illness. Yet that is not the
experience facing most individuals in the United States, only 23% of whom
die from cancer.22 Many more will die from
acute complications of an otherwise chronic condition, most likely without
a discrete terminal illness phase.3,23 Good
end-of-life care must allow for this unpredictable timing of death. In addition
to supporting those with a clearly terminal illness, we must find ways to
better assist those for whom a serious chronic illness or multiple chronic
problems present an ongoing threat of sudden exacerbation and death. End-of-life
care must also serve those who become increasingly frail, even without a life-threatening
illness. Because of a steadily diminishing reserve capacity to cope with inevitable
but unpredictable acute health challenges, these frail elderly persons may
also die without a clear terminal period. Given the variable trajectories
of dependency, our data support the idea that each group requires a different
clinical approach and different types of health services.
1.Glaser B, Strauss AL. Time for Dying. Chicago, Ill: Aldine Publishing Co; 1968.
2.Lunney JR, Lynn J, Hogan C. Profiles of older medicare decedents.
J Am Geriatr Soc.2002;50:1108-1112.Google Scholar 3.Lynn J. Serving patients who may die soon and their families: the role of hospice
and other services.
JAMA.2001;285:925-932.Google Scholar 4.Institute of Medicine. Approaching Death: Improving Care at the End of Life. Washington, DC: National Academy Press; 1997.
5.Lawton MP, Moss M, Glicksman A. The quality of the last year of life of older persons.
Milbank Q.1990;68:1-28.Google Scholar 6.Guralnik JM, LaCroix AZ, Branch LG, Kasl SV, Wallace RB. Morbidity and disability in older persons in the years prior to death.
Am J Public Health.1991;81:443-447.Google Scholar 7.Wolinsky FD, Stump TE, Callahan CM, Johnson RJ. Consistency and change in functional status among older adults over
time.
J Aging Health.1996;8:155-182.Google Scholar 8.Ferrucci L, Guralnik JM, Simonsick E, Salive ME, Corti C, Langlois J. Progressive versus catastrophic disability: a longitudinal view of
the disablement process.
J Gerontol A Biol Sci Med Sci.1996;51:M123-M130.Google Scholar 9.Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges, and nursing home admissions in
the year when older persons become severely disabled.
JAMA.1997;277:728-734.Google Scholar 10.Guralnik JM, Ferrucci L, Volpato S, Simonsick EM, Fried LP. Patterns of change in physical function [abstract].
J Am Geriatr Soc.2001;49:S12.Google Scholar 11.Verbrugge LM, Reoma JM, Gruber-Baldini AL. Short-term dynamics of disability and well-being.
J Health Soc Behav.1994;35:97-117.Google Scholar 12.Wolinsky FD, Overhage JM, Stump TE, Lubitz RM, Smith DM. The risk of hospitalization for congestive heart failure among older
adults.
Med Care.1997;35:1031-1043.Google Scholar 13.Magaziner J, Hawkes W, Hebel JR.
et al. Recovery from hip fracture in eight areas of function.
J Gerontol A Biol Sci Med Sci.2000;55:M498-M507.Google Scholar 14.Visser M, Langlois J, Guralnik JM.
et al. High body fatness, but not low fat-free mass, predicts disability in
older men and women: the Cardiovascular Health Study.
Am J Clin Nutr.1998;68:584-590.Google Scholar 15.Wolinsky FD, Tierney WM. Self-rated health and adverse health outcomes: an exploration and refinement
of the trajectory hypothesis.
J Gerontol B Psychol Sci Soc Sci.1998;53:S336-S340.Google Scholar 16.Teno JM, Weitzen S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit
other diseases?
J Palliat Med.2001;4:457-464.Google Scholar 17.Cornoni-Huntley J, Brock DB, Ostfeld AM, Taylor JO, Wallace RB, Lafferty ME. Established Populations for Epidemiologic Studies
of the Elderly. Bethesda, Md: National Institute on Aging; 1986. NIH Publication
86-2443.
18.Cornoni-Huntley J, Blazer DG, Lafferty ME, Everett DF, Brock DB, Farmer ME. Established Populations for Epidemiologic Studies
of the Elderly. Vol 2. Bethesda, Md: National Institute on Aging; 1990. NIH Publication
90-945.
19.McNeil J. Americans With Disabilities 1997. Washington, DC: US Census Bureau; 2001.
20.Federal Interagency Forum on Aging-Related Statistics. Older Americans 2000: Key Indicators of Well-Being. Washington, DC: US Government Printing Office; 2000.
21.Haan MN, Selby JV, Quesenberry Jr CP, Schmittdiel JA, Fireman BH, Rice DP. The impact of aging and chronic disease on use of hospital and outpatient
services in a large HMO: 1971-1991.
J Am Geriatr Soc.1997;45:667-674.Google Scholar 22.Minino AM, Smith BL. Deaths: preliminary data for 2000.
Natl Vital Stat Rep.2001;49:1-40.Google Scholar 23.Fox E, Landrum-McNiff K, Zhong Z, Dawson NV, Wu AW, Lynn J.for the SUPPORT Investigators. Evaluation of prognostic criteria for determining hospice eligibility
in patients with advanced lung, heart, or liver disease: Study to Understand
Prognoses and Preferences for Outcomes and Risks of Treatments.
JAMA.1999;282:1638-1645.Google Scholar